 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 1 | 1/1 | 返回列表 |
| 查看: 222 | 回復: 0 | |||
ienjoysun銀蟲 (著名寫手)
|
[交流]
EMA Review Concludes: No Cancer Risk With ARBs
|
|
EMA Review Concludes: No Cancer Risk With ARBs Shelley Wood Authors and Disclosures Posted: 10/20/2011 Pharmacist Rating: ( 0 Votes ) Rate This Article: October 20, 2011 (London, United Kingdom) — In a decision mirroring that of the US FDA in June, the European Medicines Agency (EMA) released the results of a review by its Committee for Medicinal Products for Human Use (CHMP) today, concluding that there is likely no increased risk of cancer associated with use of angiotensin-receptor blockers (ARBs) [1]. "The European Medicines Agency concludes that benefit/risk balance of angiotensin-II–receptor antagonists remains positive," a press release from the EMA states today. The EMA's review was prompted by a controversial 2010 meta-analysis, reported by heartwire , pointing to a 7.2% increased risk of new cancers--lung cancer in particular--as compared with a 6% increased risk in patients taking placebo or other heart drugs. "The CHMP reviewed all available data on the risk of cancer in patients taking ARBs, including the meta-analysis," the statement reads. "It found that the evidence from the meta-analysis was weak, noting several problems with the quality of the data, specifically that patients in the trials were not followed up for long enough to clearly establish a link between ARBs and cancer, information on the risk of cancer before start of treatment was lacking, and there was a possibility of publication bias, whereby studies that showed a link with cancer were more likely to have been included in the analysis." As chronicled by heartwire over the past year, researchers have published a raft of studies and analyses either supporting or rejecting a link between ARBs and cancer, the most recent in the October 4, 2011 issue of CMAJ, by Dr Chan Yoon (Seoul National University of Medicine, South Korea) and colleagues, actually pointing to a beneficial effect of ARBs and ACE inhibitors on the risk of cancer [2]. Another recent study, however, in diabetic patients treated with ARBs, suggested that candesartan (Atacand, AstraZeneca) was associated with a significant risk of cancer, while there was a trend toward an increased risk with telmisartan (Micardis, Boehringer Ingelheim). Commenting on the announcement, Dr Ilke Sipahi (University Hospitals Case Medical Center, Cleveland, OH), whose 2010 meta-analysis first brought this issue into the spotlight, told heartwire that he believes both the EMA and FDA "fumbled the ball." Both agencies, he notes, had the opportunity to request patient-level data from the companies and to conduct analyses that took into account drug dose, patient compliance, and duration of exposure--but neither did. "So I am very disappointed. The EMA had a total of 16 months to do this review. . . . Unfortunately, all they could do in 16 months was review the publications that came after my own. And even that review is incomplete, since there have been several studies that have come out since then supporting our findings." Repeating the criticism he had of the FDA's decision back in June, Sipahi observed that cancer biologists and epidemiologists trying to determine the cancer risk of something like smoking or an environmental toxin will pay "extreme attention" to intensity and duration of exposure. "So it's really surprising that neither of the agencies did that," he said. |
回復此樓» 猜你喜歡
求調劑一志愿武漢理工大學材料工程（085601）
已經(jīng)有7人回復
-
一志愿C9材料與化工專業(yè)總分300求調劑
已經(jīng)有4人回復
-
321求調劑
已經(jīng)有4人回復
-
307求調劑
已經(jīng)有4人回復
-
293求調劑
已經(jīng)有6人回復
-
085602 289分求調劑
已經(jīng)有3人回復
-
一志愿北京化工大學材料與化工 264分各科過A區(qū)國家線
已經(jīng)有3人回復
-
277分求調劑，跨調材料
已經(jīng)有3人回復
-
材料292調劑
已經(jīng)有6人回復
-
材料與化工考研調劑
已經(jīng)有6人回復
相關版塊跳轉
我要訂閱樓主 ienjoysun 的主題更新
| 1 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 求調劑一志愿武漢理工大學材料工程（085601） +5 | WW.' 2026-03-23 | 7/350 |
|
|---|---|---|---|---|
|
[考研] 307求調劑 +4 | 超級伊昂大王 2026-03-24 | 4/200 |
|
|
|
[考研] 一志愿華東理工大學081700，初試分數(shù)271 +5 | kotoko_ik 2026-03-23 | 6/300 |
|
|
|
[考研] 344求調劑 +3 | desto 2026-03-24 | 3/150 |
|
|
|
[考研]
 0854 考研調劑 招生了！AI 方向
+4
|
pk3725069 2026-03-19 | 16/800 |
|
|
|
[考研] 265求調劑 +10 | 梁梁校校 2026-03-17 | 10/500 |
|
|
|
[考研] 一志愿武理材料工程348求調劑 +6 | ￣^￣゜汗 2026-03-19 | 9/450 |
|
|
|
[考研] 336求調劑 +4 | 收到VS 2026-03-20 | 4/200 |
|
|
|
[考研] 336化工調劑 +4 | 王大坦1 2026-03-23 | 5/250 |
|
|
|
[考研] 311求調劑 +6 | 冬十三 2026-03-18 | 6/300 |
|
|
|
[考研] 材料與化工085600，總分304，本科有兩篇sci參與，求調劑 +4 | 幸運的醬醬 2026-03-22 | 5/250 |
|
|
|
[考研] 260求調劑 +3 | 朱芷琳 2026-03-20 | 4/200 |
|
|
|
[考研] 299求調劑 +5 | shxchem 2026-03-20 | 7/350 |
|
|
|
[考研] 268求調劑 +9 | 簡單點0 2026-03-17 | 9/450 |
|
|
|
[考研] 265求調劑 +12 | 梁梁校校 2026-03-19 | 14/700 |
|
|
|
[考研] 求調劑 +6 | Mqqqqqq 2026-03-19 | 6/300 |
|
|
|
[考研] 330求調劑 +4 | 小材化本科 2026-03-18 | 4/200 |
|
|
|
[考研] 一志愿 西北大學 ，070300化學學碩，總分287，雙非一本，求調劑。 +4 | 晨昏線與星海 2026-03-19 | 4/200 |
|
|
|
[考研]
 材料與化工 322求調劑
+4
|
然11 2026-03-19 | 4/200 |
|
|
|
[考研] 085600材料與化工調劑 324分 +10 | llllkkkhh 2026-03-18 | 12/600 |
|